^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bortezomib

    i
    Other names: LDP 341, MG 341, MLN 341, NSC 681239, PS 341, JNJ-26866138, PS-341, PS 0341, PS0341, NSC681239, LDP-341, PS341, LDP341, MLN341, MLN-341, NSC-681239
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    20h
    Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas (clinicaltrials.gov)
    P1, N=114, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    bortezomib • Copiktra (duvelisib) • Istodax (romidepsin)
    1d
    DREAMM 7: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=494, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    2d
    DREAMM 7: China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=72, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    2d
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals
    Trial initiation date
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    2d
    DREAMM 7: Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=24, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jun 2026 --> Jun 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    3d
    Bortezomib combined with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma: an exploratory clinical trial (ChiCTR2600119649)
    P=N/A, N=13, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    SOX2
    |
    carboplatin • paclitaxel • bortezomib
    4d
    Phenotypic plasticity in plasma cell myeloma: a CD138-negative case with a rare BRAF G469R mutation. (PubMed, J Pathol Transl Med)
    The patient exhibited poor response to bortezomib, lenalidomide, and dexamethasone therapy, necessitating a switch to carfilzomib-based treatment. This case underscores the diagnostic challenges of CD138-negative myeloma and highlights the importance of integrating morphology, immunophenotyping, and molecular profiling to inform accurate diagnosis and guide therapeutic strategies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD20 (Membrane Spanning 4-Domains A1) • SDC1 (Syndecan 1) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    BRAF mutation • CD20 positive
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone
    4d
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    9d
    Adding Bortezomib and Bendamustine to High-Dose Melphalan in Autologous Haematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma-A Single Centre Retrospective Study. (PubMed, EJHaem)
    Compared with standard HDM, the BBM-protocol in ASCT2 was associated with a smaller decline in progression-free survival relative to the ASCT1, and a consistent trend toward higher effectiveness across other measures. These findings suggest that BBM may help preserve efficacy in the setting of repeated transplantation and underscore the need for larger prospective studies to confirm these results.
    Retrospective data • Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    |
    bortezomib • bendamustine • melphalan
    10d
    224317: A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and older with relapsed-refractory multiple myeloma (2025-523117-28-00)
    P1/2, N=37, Not yet recruiting, Glaxosmithkline Research & Development Limited
    New P1/2 trial
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    10d
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Completed, Bristol-Myers Squibb | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    11d
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2026 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Tecvayli (teclistamab-cqyv)